Study guide
7.2 Cardiovascular & Respiratory System Disorders and Clinical Interventions
Nursing Council of Jamaica Licensure Examination / Regional Examination for Nurse Registration NCJ RENR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, NCJ Registration & the RENR Blueprint
1.1 NCJ, the Regional Councils, CXC & the Seven-Domain RENR Blueprint 1.2 Paper Format, Cognitive Levels, Exam-Day Rules & Pacing 1.3 Eligibility, Registration, Results, Reviews, Resits & NCJ Licensure
2 Chapter 2: Professional Conduct, Ethics & Legal Framework
2.1 Ethical Principles, Code of Ethics & Patient Rights 2.2 Informed Consent, Confidentiality & Jamaican Health Law 2.3 Professional Boundaries, Accountability & Incident/Error Reporting
3 Chapter 3: Health Promotion, Community Health & Wellness Maintenance
3.1 Primary Health Care, Immunization Schedules & Cold Chain Integrity 3.2 Nutrition Across the Lifespan & Maternal-Infant Wellness 3.3 Epidemiology, Vector-Borne Disease Control & Chronic Disease Prevention 3.4 Health Education, Teaching-Learning & the Determinants of Health 3.5 Communicable Disease Nursing: HIV, STIs, Tuberculosis & Leptospirosis
4 Chapter 4: Nursing Leadership, Management & Health Systems
4.1 Principles of Ward Management, Prioritization & Patient Assignment 4.2 Effective Delegation, Scope of Practice & Supervision of Unlicensed Personnel 4.3 Clinical Quality Improvement, Safety Audits & Risk Management 4.4 Disaster Preparedness, Infection Surveillance & Institutional Emergency Protocols 4.5 Leadership Styles, Management Functions, Change & Conflict Management 4.6 Caribbean Health Systems, Regional Agencies & Contemporary Health Issues
5 Chapter 5: Therapeutic Communication, Collaboration & Documentation
5.1 Principles of Therapeutic Communication & Patient-Centered Interviewing 5.2 Structured Clinical Handoffs, SBAR Technique & Critical Result Reporting 5.3 Overcoming Communication Barriers, Cultural Competence & Conflict De-escalation 5.4 Documentation, Health Records & Health Information Technology
6 Chapter 6: Nursing Practice: Nursing Process, Asepsis & Pharmacology
6.1 The Nursing Process, Nursing Diagnosis & Holistic Health Assessment 6.2 Principles of Medical and Surgical Asepsis, Standard Precautions & Isolation 6.3 Pharmacological Principles, High-Alert Medications & Safe Administration 6.4 Dosage Calculations, IV Flow Rates & Pediatric/Geriatric Dose Adjustments 6.5 Intravenous Therapy, Fluid/Electrolyte Balance & Blood Transfusion Safety
7 Chapter 7: Nursing Practice: Adult Medical-Surgical, Haematology & Oncology Care
7.1 Preoperative, Intraoperative & Postoperative Nursing Care 7.2 Cardiovascular & Respiratory System Disorders and Clinical Interventions 7.3 Gastrointestinal, Endocrine & Renal Disorders Management 7.4 Musculoskeletal, Neurological & Integumentary Care and Wound Healing 7.5 Haematology & Sickle Cell Disease 7.6 Oncology, Palliative & End-of-Life Care
8 Chapter 8: Nursing Practice: Maternal, Newborn & Reproductive Health
8.1 Antenatal Assessment, Normal Labor, Delivery & Postpartum Care 8.2 Neonatal Assessment, APGAR Scoring & Newborn Nursing Care 8.3 Reproductive Health, Family Planning & Gynaecological Conditions
9 Chapter 9: Nursing Practice: Child, Mental Health & Older Adult Care
9.1 Pediatric Growth, Developmental Milestones & Common Childhood Illnesses 9.2 Psychiatric-Mental Health Nursing, Psychopharmacology & Crisis Intervention 9.3 Depression, Substance Use Disorders & Alcohol Withdrawal 9.4 Care of the Older Adult: Delirium, Dementia, Falls & Healthy Ageing
10 Chapter 10: Clinical Decision Making: Acute Assessment & Critical Interventions
10.1 Systematic Primary and Secondary Patient Assessment (ABCDE Approach) 10.2 Early Warning Scores, Recognizing Clinical Deterioration & Escalation 10.3 Shock Syndromes: Hypovolemic, Cardiogenic, Septic & Anaphylactic 10.4 Acute Respiratory Failure, Airway Emergencies & Oxygen Delivery Modalities
11 Chapter 11: Clinical Decision Making: Complex Emergencies, Resuscitation & Trauma
11.1 Cardiopulmonary Resuscitation, Life Support Protocols & Arrhythmia Recognition 11.2 Acute Coronary Syndromes & Cerebrovascular Accidents (Stroke) 11.3 Acute Diabetic & Metabolic Crises: DKA, HHS & Severe Hypoglycemia 11.4 Trauma, Burns, Poisoning & Environmental Emergencies
12 Chapter 12: Professional Development & Evidence-Based Practice
12.1 Reflective Nursing Practice & Clinical Competence Assessment 12.2 Evidence-Based Practice, Research Utilization & Nursing Quality 12.3 Continuing Professional Education, NCJ License Renewal & Lifelong Learning
7.2 Cardiovascular & Respiratory System Disorders and Clinical Interventions
Key Takeaways Explain This Topic AI
Heart failure manifestations diverge anatomically: left-sided failure precipitates pulmonary venous congestion, crackles, orthopnea, and paroxysmal nocturnal dyspnea, whereas right-sided failure produces systemic venous congestion, jugular venous distention, hepatomegaly, and dependent pitting edema.
Safe cardiac glycoside management requires auscultating the apical pulse for a full 60 seconds prior to administering digoxin, withholding for an adult heart rate below 60 bpm, and monitoring serum potassium because hypokalemia drastically potentiates digoxin toxicity.
Peripheral arterial disease produces intermittent claudication, dependent rubor, and ischemic ulcers relieved by resting with legs dependent, in stark contrast to peripheral venous disease, which causes chronic edema, stasis dermatitis, and malleolar ulcers improved by leg elevation.
Chronic hypercapnic respiratory failure in severe COPD necessitates controlled low-flow oxygen titration targeting an SpO2 of 88% to 92% to optimize cellular oxygenation without blunting the hypoxemic ventilatory drive.
Drug-susceptible pulmonary TB is treated with 2 months of rifampicin, isoniazid, pyrazinamide and ethambutol, then 4 months of rifampicin and isoniazid, with monitoring for hepatotoxicity, neuropathy and optic neuritis.
Last updated: October 2026
Cardiovascular & Respiratory System Disorders and Clinical Interventions
Clinical Core: Cardiorespiratory disorders represent leading contributors to global adult morbidity. Optimal bedside management demands acute clinical discernment to distinguish between arterial and venous pathologies, differentiate left- from right-sided ventricular failure, titrate targeted oxygen delivery in chronic carbon dioxide retainers, and execute complex antimicrobial regimens while anticipating toxicities.
- Cardiovascular Disorders: Hypertension, CAD & Heart Failure
- Hypertension Classification and Pharmacotherapy
Thresholds differ by guideline. The American College of Cardiology/American Heart Association defines hypertension as ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg (2017, retained in 2025). WHO (2021), the International Society of Hypertension (2020) and many Caribbean programmes diagnose it at ≥ 140 / 90 mmHg \ge 140/90\text{ mmHg} ≥ 140/90 mmHg on repeated readings. Management combines non-pharmacological interventions (the Dietary Approaches to Stop Hypertension [DASH] diet rich in fruits, vegetables, and low-fat dairy; sodium restriction to less than 2 , 000 mg/day 2,000\text{ mg/day} 2 , 000 mg/day ; regular aerobic exercise; weight loss; and alcohol moderation) with targeted pharmacotherapy:
Angiotensin-Converting Enzyme (ACE) Inhibitors (e.g., lisinopril, enalapril): Block conversion of angiotensin I to the potent vasoconstrictor angiotensin II. Key adverse effects include hyperkalemia, angioedema (life-threatening airway compromise), and a persistent, dry, hacking cough secondary to bradykinin accumulation. If cough proves intolerable, clients are transitioned to Angiotensin Receptor Blockers (ARBs).
Angiotensin Receptor Blockers (ARBs) (e.g., losartan, valsartan): Selectively block angiotensin II receptors, lowering vascular resistance without causing bradykinin accumulation.
Calcium Channel Blockers (CCBs) (e.g., amlodipine, diltiazem): Inhibit calcium influx into vascular smooth muscle and myocardium, inducing systemic vasodilation. Notable adverse reactions include peripheral dependent edema, headache, flushing, and bradycardia (with non-dihydropyridines like diltiazem and verapamil).
Thiazide Diuretics (e.g., hydrochlorothiazide): Inhibit sodium and chloride reabsorption in the distal convoluted tubule. Nurses must monitor for hypokalemia, hyponatremia, and hyperuricemia (which can precipitate acute gouty attacks).
Coronary Artery Disease & Acute Coronary Syndromes (ACS)
Coronary artery disease (CAD) progresses from stable angina (predictable substernal chest discomfort relieved by rest or sublingual nitroglycerin) to Acute Coronary Syndromes (unstable angina, Non-ST-Segment Elevation Myocardial Infarction [NSTEMI], and ST-Segment Elevation Myocardial Infarction [STEMI]).
Emergency Nursing Interventions: The nurse immediately initiates the MONA protocol and rapid diagnostic triage upon presentation with ischemic chest pain:
Obtain a 12-lead electrocardiogram (ECG) within 10 minutes of client arrival to assess for ST-segment elevation, ST depression, or T-wave inversion.
Aspirin: Administer 162 mg 162\text{ mg} 162 mg to 325 mg 325\text{ mg} 325 mg of non-enteric coated chewable aspirin immediately to inhibit platelet aggregation.
Nitroglycerin: Administer sublingual nitroglycerin (0.4 mg) every 5 minutes up to a maximum of 3 doses, reassessing pain and blood pressure before each dose. Contraindications: SBP < 90 mmHg <90\text{ mmHg} < 90 mmHg , severe bradycardia ( < 50 bpm <50\text{ bpm} < 50 bpm ), right ventricular infarction, or concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil within 24 hours, tadalafil within 48 hours) due to refractory, fatal hypotension.
Oxygen: Titrated only if oxygen saturation drops below 90 % 90\% 90% or if the client is dyspneic.
Morphine: Intravenous morphine sulfate ( 2 mg 2\text{ mg} 2 mg to 4 mg 4\text{ mg} 4 mg ) for persistent chest pain refractory to nitrates; dilates venous capacitance vessels and reduces myocardial preload and anxiety.
Cardiac Biomarkers: Serial Cardiac Troponin I and T measurements are the gold standard for detecting myocardial necrosis, rising within 3 to 4 hours post-infarction and persisting for up to 10 to 14 days.
Heart Failure: Left-Sided Versus Right-Sided Failure
Heart failure (HF) occurs when the heart cannot pump sufficient blood to meet metabolic tissue demands. The New York Heart Association (NYHA) functional classification categorizes impairment from Class I (no symptoms with ordinary physical activity) to Class IV (inability to carry on any physical activity without discomfort; symptoms present at rest).
Assessment Parameter Left-Sided Heart Failure (Ventricular Failure) Right-Sided Heart Failure (Cor Pulmonale / Systemic Congestion)
Primary Pathophysiology Left ventricle fails to pump effectively; blood backs up into the left atrium and pulmonary veins. Right ventricle fails; blood backs up into the right atrium and systemic venous circulation.
Respiratory Manifestations Dyspnea on exertion, orthopnea (inability to breathe flat), paroxysmal nocturnal dyspnea (PND), tachypnea. Typically secondary to pulmonary pathology; clear lungs on auscultation unless caused by advanced left HF.
Auscultation Findings Bilateral inspiratory crackles (bibasilar rales), wheezing ("cardiac asthma"), presence of an S 3 S_3 S 3 ventricular gallop. Normal pulmonary auscultation; possible tricuspid murmur.
Sputum Characteristics Persistent hacking cough; pink, frothy sputum in acute pulmonary edema (medical emergency). Non-productive cough or absent sputum.
Systemic & Vascular Signs Fatigue, weakness, oliguria during day, nocturia at night, pale/cool skin, decreased ejection fraction. Jugular venous distention (JVD) at 45 degrees, hepatomegaly, splenomegaly, right upper quadrant pain.
Fluid Retention Patterns Pulmonary vascular congestion; weight gain. Dependent pitting edema (ankles, sacrum), abdominal ascites , anasarca, anorexia/nausea from GI congestion.
B-Type Natriuretic Peptide (BNP): Released by ventricular myocytes in response to stretching and elevated filling pressures. A serum BNP > 100 pg/mL >100\text{ pg/mL} > 100 pg/mL confirms heart failure as the primary etiology of acute dyspnea, distinguishing it from primary pulmonary disorders.
Loop Diuretics (e.g., Furosemide): Administered to reduce preload and pulmonary congestion. Nurses must monitor for hypokalemia ( K + < 3.5 mEq/L K^+ <3.5\text{ mEq/L} K + < 3.5 mEq/L ), hypotension, and ototoxicity if administered too rapidly via IV push (maximum rate 20 mg/min 20\text{ mg/min} 20 mg/min ). Clients are instructed to record daily morning weights after voiding; a weight gain of ≥ 2 to 3 lbs (0.9 to 1.4 kg) \ge 2\text{ to } 3\text{ lbs (0.9 to 1.4 kg)} ≥ 2 to 3 lbs (0.9 to 1.4 kg) in 24 hours or 5 lbs (2.3 kg) 5\text{ lbs (2.3 kg)} 5 lbs (2.3 kg) in one week indicates acute fluid decompensation requiring provider notification.
Digoxin Therapy and Toxicity: Digoxin provides positive inotropic (increases contractility) and negative chronotropic (slows heart rate) effects. It has a narrow therapeutic range, traditionally quoted as 0.5 to 2.0 ng/mL . Heart failure guidance now aims for about 0.5–0.9 ng/mL.
Nursing Imperative: The nurse must auscultate the apical pulse for a full 60 seconds prior to administration; the dose is withheld if the apical pulse is < 60 bpm <60\text{ bpm} < 60 bpm in adults (or < 70 bpm <70\text{ bpm} < 70 bpm in children).
Toxicity Manifestations: Early gastrointestinal signs include anorexia, nausea, vomiting, and diarrhea. Neurological signs include fatigue, headache, and confusion. Visual disturbances are pathognomonic: photophobia, blurred vision, and yellow-green halos around lights . Cardiac toxicity produces dangerous bradydysrhythmias and ventricular ectopic beats.
Electrolyte Warning: Hypokalemia drastically potentiates digoxin toxicity because potassium and digoxin compete for identical binding sites on the myocardial cell membrane N a + / K + Na^+/K^+ N a + / K + -ATPase pump. The nurse must check serum potassium before giving digoxin; antidote for life-threatening toxicity is Digoxin immune Fab (Digibind) .
Peripheral Vascular Disease: Arterial Versus Venous Insufficiency
Differentiating peripheral arterial disease (PAD) from peripheral venous disease (PVD) is essential to avoid catastrophic nursing errors, such as elevating an ischemic arterial limb or dangling a venous stasis leg.
Clinical Characteristic Peripheral Arterial Disease (PAD) Peripheral Venous Disease (PVD)
Etiology & Mechanism Arteriosclerosis and luminal narrowing impair oxygenated arterial blood flow to distal tissues. Incompetent venous valves and venous hypertension impede return of blood to the heart.
Pain Characteristics Intermittent claudication: Sharp, cramping muscular pain provoked by walking, relieved promptly by rest. Severe disease causes rest pain in toes/forefoot at night. Dull, heavy, aching pain worsened by prolonged standing or dependency; relieved by elevation.
Skin Color & Temperature Dependent rubor (deep fiery red when leg dangles) and elevation pallor (chalky white when raised); skin is cool or cold to touch. Normal temperature or warm; stasis dermatitis with brown, rust-colored hyperpigmentation (hemosiderin deposits).
Skin Texture & Trophic Changes Thin, shiny, taut skin; complete loss of hair on toes/shins; thick, ridged, brittle toenails. Thick, hardened, brawny skin ("woody" texture); presence of chronic cellulitis or dermatitis.
Peripheral Pulses Diminished, weak, or completely absent dorsalis pedis and posterior tibial pulses. Normal, bounding arterial pulses (though pulses may be difficult to palpate beneath severe pitting edema).
Edema Minimal or completely absent. Moderate to severe dependent pitting edema around ankles and calves.
Ulcer Characteristics Arterial Ulcers: Located on tips of toes, web spaces, heels, or lateral malleolus. Deep, punched-out round margins, pale or black necrotic (eschar) base, minimal exudate; very painful. Venous Ulcers: Located around the medial malleolus . Shallow, irregular borders, beefy red granulating base, copious yellow exudate ; moderate or mild pain.
Therapeutic Positioning Dangle legs down (dependent position) to utilize gravity to assist arterial perfusion; never elevate above heart. Elevate legs above heart level (at least 20 minutes 4 times daily) to facilitate venous drainage; avoid crossing legs.
- Respiratory System Disorders: COPD, Asthma, Pneumonia & Tuberculosis
- Chronic Obstructive Pulmonary Disease (COPD) and the Hypoxic Drive
COPD is characterized by persistent, progressive airflow limitation comprising two overlapping phenotypes:
Emphysema: Abnormal, permanent enlargement of air spaces distal to terminal bronchioles with alveolar wall destruction and loss of lung elastic recoil. Clients present as "pink puffers" with tachypnea, cachexia, a barrel chest (anteroposterior-to-transverse thoracic diameter ratio 1:1), and use pursed-lip breathing (which generates positive end-expiratory pressure, staving off premature airway collapse during expiration).
Chronic Bronchitis: Clinically defined as a chronic, productive cough for at least 3 consecutive months in 2 consecutive years . Characterized by goblet cell hyperplasia and mucus hypersecretion. Clients present as "blue bloaters" with cyanosis, chronic hypoxemia, hypercapnia, secondary erythrocytosis (elevated hematocrit), and peripheral edema from secondary right-sided heart failure ( cor pulmonale ).
The Hypoxic Drive Clinical Nuance: In healthy individuals, central brainstem chemoreceptors regulate ventilation primarily in response to arterial carbon dioxide tension ( P a C O 2 PaCO_2 P a C O 2 ). In clients with severe, end-stage chronic hypercapnia, central chemoreceptors become desensitized to elevated C O 2 CO_2 C O 2 . Consequently, respiratory drive shifts partially to peripheral chemoreceptors in the carotid and aortic bodies, which respond to arterial hypoxemia ( hypoxic drive ). Administering uncontrolled, high concentrations of oxygen eliminates this hypoxic stimulus, causing hypoventilation, severe C O 2 CO_2 C O 2 retention ( C O 2 CO_2 C O 2 narcosis), respiratory acidosis, and lethargy. The nurse provides controlled, low-flow oxygen via nasal cannula (1 to 2 L/min) or a precise Venturi mask , titrating oxygen to maintain an S p O 2 SpO_2 Sp O 2 of 88% to 92% . Current physiology attributes much oxygen-induced hypercapnia to worsening ventilation-perfusion mismatch and the Haldane effect, not only to loss of hypoxic drive. Either way, the target range is the same.
Asthma: Pathophysiology, Exacerbations & Peak Flow Tracking
Asthma is a chronic inflammatory disorder characterized by bronchial hyperresponsiveness, reversible bronchospasm, mucosal edema, and thick mucus production.
Pharmacological Distinction:
Rescue Bronchodilator: Short-acting beta2-agonists ( SABA , e.g., albuterol) act within minutes to relax bronchial smooth muscle during acute attacks. Common side effects include tremors and tachycardia.
Maintenance Controller: Inhaled corticosteroids ( ICS , e.g., fluticasone, budesonide) provide daily baseline anti-inflammatory control. Clients must rinse their mouth and gargle with water, spitting it out after every inhalation , to prevent oral candidiasis (thrush) and dysphonia.
Peak Expiratory Flow Rate (PEFR) Monitoring: Clients use a handheld peak flow meter to establish a "personal best" and guide daily action plans:
Green Zone (80% to 100% of personal best): Good control; no symptoms present; continue routine daily maintenance medications.
Yellow Zone (50% to 79% of personal best): Caution; indicates airway narrowing or impending exacerbation. The client must take their prescribed inhaled SABA rescue medication and recheck peak flow.
Red Zone (<50% of personal best): Medical alert; severe airway obstruction. The client must immediately administer their rescue bronchodilator and seek emergency medical evaluation.
Status Asthmaticus & The Silent Chest: An acute, severe asthma attack refractory to bronchodilators. If a client with loud wheezing suddenly exhibits a "silent chest" with diminished breath sounds and no audible wheeze, this is an ominous sign of impending respiratory arrest due to critical airway closure and exhaustion; immediate endotracheal intubation is indicated.
Pneumonia: Diagnostics, Collection & Nursing Management
Infectious inflammation of the lung parenchyma leads to alveolar exudative consolidation. Bacterial pneumonia (most commonly Streptococcus pneumoniae ) manifests with abrupt fever, shaking chills, tachypnea, productive cough with rust-colored or purulent sputum, pleuritic chest pain, dullness to percussion, and bronchial breath sounds with inspiratory crackles.
Sputum Specimen Collection Protocol: Sputum must be collected before initiating antibiotic therapy to ensure accurate microbiological identification. The nurse instructs the client to rinse their mouth with water (not mouthwash) to clear oral flora, take three deep breaths, and produce a deep, forceful cough from the bronchial tree into a sterile specimen cup upon awakening in the morning. Saliva is unacceptable.
Bedside Interventions: Position client in semi-Fowler's to high-Fowler's position; maintain oral or IV hydration of 2 to 3 L/day to liquefy viscous secretions; assist with incentive spirometry 10 times hourly while awake; provide chest physiotherapy; and administer supplemental humidified oxygen.
Pulmonary Tuberculosis & The 4-Drug RIPE Regimen
Pulmonary tuberculosis (TB) is caused by Mycobacterium tuberculosis and transmitted via airborne droplet nuclei. Clinical manifestations include low-grade afternoon fevers, drenching night sweats, chronic productive cough lasting > 3 >3 > 3 weeks, hemoptysis, anorexia, and unexplained weight loss.
Diagnostic Testing:
Mantoux Tuberculin Skin Test (PPD): 0.1 mL 0.1\text{ mL} 0.1 mL of purified protein derivative is injected intradermally, creating a 6 to 10 mm wheal. Read 48 to 72 hours later by palpating the transverse diameter of induration (firm swelling) , not erythema.
≥ 5 mm \ge 5\text{ mm} ≥ 5 mm induration: Positive in HIV-infected individuals, immunosuppressed clients (e.g., organ transplant recipients, prednisone ≥ 15 mg/day \ge 15\text{ mg/day} ≥ 15 mg/day ), or close contacts of active TB cases.
≥ 10 mm \ge 10\text{ mm} ≥ 10 mm induration: Positive in healthcare workers, immigrants from high-prevalence countries within 5 years, injection drug users, and clients with high-risk clinical conditions (diabetes, chronic renal failure).
≥ 15 mm \ge 15\text{ mm} ≥ 15 mm induration: Positive in all persons with no known risk factors for TB.
Confirmation: WHO recommends a rapid molecular test (such as Xpert MTB/RIF) as the initial test where available, because it also detects rifampicin resistance. Sputum smear for acid-fast bacilli (AFB) and culture are also used.
The First-Line RIPE Regimen: For drug-susceptible TB, give all four drugs for a 2-month intensive phase , then isoniazid and rifampicin for a 4-month continuation phase (2HRZE/4HR). Doses are given as directly observed therapy to prevent resistance (Section 3.5):
R — Rifampin (RIF): Causes red-orange discoloration of bodily fluids (urine, saliva, tears, sweat); permanently stains contact lenses. Induces hepatic cytochrome P450 enzymes, significantly decreasing the efficacy of oral contraceptives, warfarin, and protease inhibitors. Baseline and periodic liver function tests (LFTs) required.
I — Isoniazid (INH): Potent bactericidal agent; carries a black-box warning for severe hepatotoxicity (monitor for jaundice, dark urine, elevated AST/ALT; instruct client to avoid alcohol). Causes peripheral neuropathy (paresthesias, numbness in hands/feet) by depleting pyridoxine (vitamin B6); co-administration of Vitamin B6 (pyridoxine, 25 to 50 mg daily) is mandatory for prevention.
P — Pyrazinamide (PZA): Inhibits renal uric acid excretion, causing hyperuricemia and precipitating acute gouty arthritis, along with hepatotoxicity. Monitor serum uric acid and liver enzymes.
E — Ethambutol (EMB): Bacteriostatic agent; major adverse effect is optic neuritis , causing decreased visual acuity, loss of red-green color discrimination, and central scotomas. Baseline and monthly visual acuity (Snellen chart) and color vision testing are required; the medication must be discontinued immediately if visual disturbances arise.